Article
After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its c
Rating:
0.0
Views:
76
Likes:
1
Library:
1
While the comeback plan for its lead drug is still up in the air, ImmunoGen says it has a second shot at an antibody-drug conjugate breakthrough. The FDA has granted breakthrough therapy designation to IMGN632, which targets CD123, in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm. The aggressive cancer
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value